Kas OraSure Technologies dividend on kindel?
OraSure Technologies on suurendanud dividendi juba 0 aastat.
Viimase 10 aasta jooksul on OraSure Technologies seda igal aastal 0 % alandatud.
5-aastases perspektiivis langes dividendimakse 0 %.
Analaütikud prognoosivad käesolevaks majandusaastaks Dividendide vähendamine kasvu −100,000%.
OraSure Technologies Aktienanalyse
Mis teeb OraSure Technologies?
OraSure Technologies Inc. is a US company specializing in the development, manufacturing, and marketing of diagnostic medical products. It was founded in 1987 under the name SolarCare Technologies Corporation and changed its name to OraSure Technologies Inc. in 2000. The company's main goal is to reduce the prevalence of infectious diseases and improve global health. It focuses on four core areas: infectious diseases, microfluidic analysis, application management, and genomics. In the field of infectious diseases, OraSure Technologies Inc. produces various rapid tests for detecting diseases such as HIV, Hepatitis C, and Syphilis. It also offers tests for drug and alcohol consumption verification. In microfluidic analysis, the company produces devices and test kits for biomedical research and clinical use. These technologies allow for the quick analysis of small samples and accurate results. Application management is another important aspect of the company, offering cloud-based applications for optimized data and information management. These applications help businesses and institutions obtain real-time data and use data analytics tools. Additionally, OraSure Technologies Inc. is involved in genomics and offers various products and services related to DNA sequencing. The company has a broad customer base, ranging from government agencies and research institutions to service companies and private clinics. It operates in numerous countries worldwide. An example of a product from OraSure Technologies is the OraQuick HIV self-test, which allows individuals to determine within 20 minutes whether they are infected with the HIV virus or not. This is particularly important for people who cannot or do not want to visit a doctor and value their privacy. OraSure Technologies' history is marked by numerous innovations and significant milestones. One notable event was the development of the first oral HIV rapid test in 2004, which allowed for quick and reliable detection of the virus through a saliva sample instead of a blood sample. In recent years, the company has increased its investment in research and development and formed partnerships with companies and institutions to bring innovative diagnostic medical products to the market. In summary, OraSure Technologies Inc. is a leading US company specializing in the development, manufacturing, and marketing of diagnostic medical products. With a focus on infectious diseases, microfluidic analysis, application management, and genomics, the company has a wide range of products and a broad customer base. OraSure Technologies is an innovative company striving to improve global health through partnerships and investments in research and development. OraSure Technologies on üks populaarsemaid ettevõtteid saidil Eulerpool.com.Aktsiasäästuplaanid pakuvad investoritele atraktiivset võimalust pikema aja jooksul vara koguda. Üheks peamiseks eeliseks on nn keskmise maksumuse efekt: investeerides regulaarselt kindla summa aktsiatesse või aktsiafondidesse, ostetakse automaatselt rohkem osakuid siis, kui hinnad on madalad, ja vähem, kui need on kõrged. See võib aja jooksul viia soodsama keskmise hinna per osakuni. Lisaks võimaldavad aktsiasäästuplaanid ka väikeinvestoritel pääseda ligi kallimatele aktsiatele, kuna nendega saab liituda juba väikeste summadega. Regulaarne investeerimine soodustab ka distsiplineeritud investeerimisstrateegiat ja aitab vältida emotsionaalsete otsuste, nagu impulsiivne ostmine või müümine. Peale selle saavad investorid osa aktsiate võimalikust väärtuse kasvust ning dividendide väljamaksetest, mida saab reinvesteerida, mis tugevdab intressiintressi efekti ning seeläbi investeeritud kapitali kasvu.